Abstract: The use of a probiotic Lactobacillus rhamnosus and a probiotic Bifidobacterium longumin the manufacture of a medicament or therapeutic nutritional composition for administration to an infant during at least the first three months of life for the long-term prophylaxis of diarrhoea in infants and young children.

Abstract: The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for preventing or treating diarrhoea in infants delivered by caesarean section.

Abstract: The use of Bifidobacterium lactis CNCM 1-3446 in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants delivered by caesarean section is disclosed.

Abstract: The use of a probiotic strain of Lactobacillus rhamnosus and an oligosaccharide mixture which comprises 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising GalNAc?1,3Gal?1,4Glc and Gal?1,6GalNAc?1,3Gal?1,4Glc, 20-90 wt % of at least one neutral oligosaccharide selected from the group comprising Gal?1,6Gal, Gal?1,6Gal?1,4Glc Gal?1,6Gal?1,6Glc, Gal?1,3Gal?1,3Glc, Gal? 1,3Gal? 1,4GIc, Gal? 1,6Gal? 1,6Gal? 1,4GIc, Gal? 1,6Gal? 1,3Gal? 1,4GIc Gal?1,3Gal?1,6Gal?1,4Glc and Gal?1,3Gal?1,3Gal?1, 4GIc and 5-50 wt % of at least one sialylated oligosaccharide selected from the group comprising NeuAc?2,3Gal?1,4GIc and NeuAc?2,6Gal?1,4Glc in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants delivered by caesarean section is disclosed.

Abstract: Protein hydrolyzates are used for prevention of bacterial overgrowth. In addition it was shown in sucklings mammals that specific protein hydrolyzates promote an intestinal flore pattern which is similar to the one of mammals raised by their mother. Other advantages are that the hydrolyzate is easier to obtain and simpler to administrate than treatment of bacterial overgrowth with the aid of active principles.

Abstract: The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of bifidobacterium longum ATCC BAA-999.

Abstract: The use of a whey predominant protein source and lactose in the manufacture of a nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants fed with the nutritional composition wherein the nutritional composition has a protein content of less than 2.1 g protein/100 kcal and a phosphorus content of less than 40 mg/100 kcal.

Abstract: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.

Abstract: The present invention provides novel strains of probiotics for use in the gastrointestinal tract of a pet. The probiotics of the present invention are capable of fermenting starch to produce lactic acid and/or hydrogen peroxide anti-pathogenic metabolites. The present invention also provides a novel method for identifying the effectiveness of a pet probiotic in vitro. The method simulates the introduction of a probiotic candidate in the gastrointestinal tract of a pet and measures the anti-pathogenic effectiveness of the probiotic.

Abstract: The present invention provides novel strains of probiotics for use in the gastrointestinal tract of a pet. The probiotics of the present invention are capable of fermenting starch to produce lactic acid and/or hydrogen peroxide anti-pathogenic metabolites. The present invention also provides a novel method for identifying the effectiveness of a pet probiotic in vitro. The method simulates the introduction of a probiotic candidate in the gastrointestinal tract of a pet and measures the anti-pathogenic effectiveness of the probiotic.

Abstract: The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same.

Abstract: The present invention pertains to a composition for inducing a pattern of gut barrier maturation similar to that observed with breast-feeding and able to improve gut barrier maturation, e.g. during neonatal stress. In particular, the present invention relates to an infant formula containing a combination of specific ingredients designed to provide a synergistic effect all along gastrointestinal tract and barrier function.

Abstract: The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same.

Abstract: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.

Abstract: A nutritional composition is disclosed which comprises synergistic functional carbohydrates for preventing or treating infection by pathogenic bacteria and/or promoting gut flora balance and health. The carbohydrates have a synergistic activity on promoting bifidobacteria in the intestine. Also disclosed are a method of production of the composition; and a method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an effective amount of the composition.

Abstract: The present invention relates to a nutritional composition which is liquid and shelf-stable or powdered and reconstitutable. The composition has a fiber content of more than 2.5 g/fibber per 100 ml of the composition. Furthermore, it has an energy content of 1.3-1.8 kcal/ml. The composition is useful to improve and maintain gut comfort, restoring a well-balanced gut flora, especially in an elderly patient prone to malnutrition. The invention further relates to a process for preparing the nutritional composition.

Abstract: A prebiotic for enhancement of an immune response, a nutritional composition for enhancement of an immune response; use of a prebiotic in the manufacture of a medicament or nutritional composition for enhancement of an immune response; use of a prebiotic in the manufacture of a medicament or nutritional composition for the prevention or treatment of measles; a method of enhancing an immune response which comprises administering an effective amount of a prebiotic; and a method of prevention or treatment of measles which comprises administering an effective amount of a prebiotic. In preferred embodiments the prebiotic comprises a fructo-oligosaccharide.

Abstract: A method for selectively increasing the production of propionate in the gastro-intestinal tract of a mammal. The method includes the step of enterally administering to the mammal a nutritional composition which contains dextran. Increasing the propionate production results in decreased blood cholesterol levels, decreased blood triglyceride levels, decreased very low density lipoprotein levels, increased high density lipoprotein levels, and increased insulin sensitivity.

Abstract: Novel microorganisms of the family Lactobacillaceae, particularly microorganisms of the gnus Lactobacillus, that are useful in preventing or treating diarrhoea are provided. The microorganism can be utilized for the preparation of an ingestable support and to a composition containing same. The microorganism Lactobacillus paracasei CNCM I-2116 can be included.

Abstract: The present invention pertains to novel microorganisms of the genus Bifidobacterium, that are useful in preventing diarrhea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestable support and to a composition containing the same.